Most breast cancer patients return to working same hours

Share this article:
Most Breast Cancer Patients Return to Working Same Hours
Most Breast Cancer Patients Return to Working Same Hours

(HealthDay News) -- Nearly three-quarters of women treated for breast cancer return to their prediagnosis working time, according to a study published online July 9 in the Journal of Clinical Oncology.

To examine changes in working time 16 months after a breast cancer diagnosis, Marie Høyer, R.N., from the Uppsala University Hospital in Sweden, and colleagues identified patients with breast cancer using the Regional Breast Cancer Quality Register of Central Sweden. Questionnaires were completed at baseline and follow-up (average of four and 16 months after diagnosis) by 505 women (younger than 63 years at diagnosis).

Compared with prediagnosis working time, at follow-up the researchers found that 72 percent reported no change, 2 percent reported an increase, 15 percent reported a decrease, and 11 percent did not work. The likelihood of job discontinuation/decreased working time was increased for patients undergoing chemotherapy (odds ratio [OR], 2.45). For chemotherapy recipients, full-time work prediagnosis (OR, 3.25), cancer-related work limitations (OR, 5.26), and less value attached to work (OR, 3.69) correlated with decreased working time. Among patients not receiving chemotherapy, older age (OR, 1.09) and less value attached to work (OR, 5.00) correlated with decreased working time.

"Chemotherapy and cancer-related work limitations are important factors to take into account to identify women in need of support," the authors write. "It is also essential to consider that a breast cancer diagnosis may be followed by a reassessment of life goals. Thus, not returning to work or decreasing working time may be the optimal outcome for some women."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Poor staging linked to mortality in bladder cancer

Poor staging linked to mortality in bladder cancer

In cases of bladder cancer, omission of muscle in specimen or its mention in pathology report is linked to increased mortality.

Daily aspirin may lower mortality in nonmetastatic prostate cancer

Daily aspirin may lower mortality in nonmetastatic prostate ...

Even a small daily dose of aspirin may help lower mortality among men with nonmetastatic prostate cancer, according to research.

Irinotecan plus bevacizumab ups outcome for metastatic colorectal cancer (CRC)

Irinotecan plus bevacizumab ups outcome for metastatic colorectal ...

Findings show benefits compared with FOLFIRI for patients with untreated metastatic disease.